You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 26, 2026

Claims for Patent: 10,981,942

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 10,981,942

Title:	Crystalline form of benzylbenzene SGLT2 inhibitor
Abstract:	Provided are crystalline forms of a compound having an inhibitory effect on sodium-dependent glucose cotransporter SGLT2. The invention also provides pharmaceutical compositions, methods of preparing the crystalline compound, and methods of using the crystalline compound, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT or SGLT2 inhibition.
Inventor(s):	Mengzhuang Cai, Qian Liu, Ge Xu, Binhua Lv, Brian Seed, Jacques Roberge
Assignee:	Theracosbio LLC
Application Number:	US16/694,642
Patent Claims:	1. A crystalline form of the compound of the formula: characterized by a Raman spectra that comprises three or more peaks at about 353, 688, 825, 1178, 1205, 1212, 1608, 2945, 3010 and 3063 cm−1. 2. The crystalline form in accordance with claim 1, characterized by a Raman spectra that comprises peaks at about 353, 688, and 825 cm−1. 3. The crystalline form in accordance with claim 1, characterized by a Raman spectra that comprises peaks at about 1178, 1205, and 1212 cm−1. 4. The crystalline form in accordance with claim 1, characterized by a Raman spectra that comprises peaks at about 1608, 2945, 3010 and 3063 cm−1. 5. The crystalline form in accordance with claim 1, characterized by a Raman spectra that comprises peaks at about 353, 688, 825, 1608, 2945, 3010 and 3063 cm−1. 6. The crystalline form in accordance with claim 1, characterized by a Raman spectra that comprises peaks at about 1178, 1205, 1212, 1608, 2945, 3010 and 3063 cm−1. 7. The crystalline form in accordance with claim 1, characterized by a Raman spectra that comprises peaks at about 353, 688, 825, 1178, 1205, and 1212 cm−1. 8. The crystalline form in accordance with claim 1, characterized by the Raman peaks substantially in accordance with those of FIG. 4. 9. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a crystalline form of the compound of claim 1. 10. The crystalline form in accordance with claim 1, characterized by a Raman spectra that comprises peaks at about at about 353, 688, 825, 1178, 1205, 1212, 1608, 2945, 3010 and 3063 cm−1.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.